Xigamax NT Tablet SR is a sustained-release formulation combining Pregabalin 75 mg and Nortriptyline 10 mg, designed for the management of neuropathic pain and certain chronic pain conditions. Pregabalin, a gamma-aminobutyric acid (GABA) analogue, modulates calcium channels in the central nervous system, reducing neurotransmitter release and thereby alleviating neuropathic pain and seizures. Nortriptyline, a tricyclic antidepressant, inhibits the reuptake of norepinephrine and serotonin, enhancing descending inhibitory pain pathways and providing additional analgesic effects. The sustained-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing peak-related adverse effects. Xigamax NT is indicated for peripheral and central neuropathic pain, post-herpetic neuralgia, diabetic neuropathy, fibromyalgia, and adjunctive therapy in certain chronic pain syndromes. Common side effects may include dizziness, somnolence, dry mouth, constipation, and potential cardiovascular effects such as orthostatic hypotension. Caution is advised in patients with a history of cardiac arrhythmias, glaucoma, or renal impairment. Dose adjustments may be necessary based on clinical response and tolerability. Xigamax NT should be prescribed under medical supervision, with gradual titration to minimize adverse effects and to optimize therapeutic outcomes. It is contraindicated in patients with hypersensitivity to either component or related compounds.